Novo Nordisk (NYSE: NVO) stock tumbled 3.9% through 10:45 a.m. ET this morning after the manufacturer of GLP-1 weight loss drugs announced its CEO, Lars Fruergaard Jørgensen, will step down from ...

Johnny Rice has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.

While not super cheap today, at 26 times trailing earnings and with growth prospects perking up, it may be time to take another look at Novo Nordisk stock. Rich Smith has no position in any of the ...

Stock Advisor returns as of May 12, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. The views and ...